Multiple Myeloma Research Foundation

The MMRF is led by an executive leadership team and a board of directors composed of industry leaders and investors. Specific investment decisions, particularly for the Myeloma Investment Fund, are guided by the foundation's Scientific Advisory Board and internal research leadership, though named individuals are not publicly disclosed beyond the executive team.

The MMRF sources investment opportunities through its deep network of researchers, clinicians, and industry partners in the multiple myeloma field. Its Myeloma Investment Fund (MIF) targets biotechnology companies with promising new therapies, leveraging the foundation's comprehensive CoMMpass Study and patient data to identify high-impact interventions.

The MMRF operates as a nonprofit medical research foundation, but its Myeloma Investment Fund (MIF) functions similarly to a venture capital arm, making equity-style investments in early-stage biotech companies. This hybrid structure allows it to directly fund research while also supporting commercial drug development.

The MMRF primarily targets early-stage and translational research through its Myeloma Investment Fund, focusing on biotechnology companies developing novel multiple myeloma treatments. It also supports clinical trials at various stages, including Phase I, II, and III, through its research grants and partnerships.

The MMRF collaborates with pharmaceutical companies, academic institutions, and other research foundations on clinical trials and data-sharing initiatives. Its CoMMpass Study, for example, is a collaborative effort with multiple partners to share genomic and clinical data, but the foundation does not publicly disclose co-investment structures in its MIF portfolio.

The MMRF raises funds through individual donations, corporate partnerships, fundraising events like Team for Cures, and its Myeloma Investment Fund returns. It does not operate as a single-family office and derives its capital from philanthropic support rather than a single benefactor.

The MMRF itself is a nonprofit organization, and its philanthropic and research activities are consolidated under its single corporate structure. The Myeloma Investment Fund is operated as a program within the foundation, with investment returns reinvested into the mission. The foundation is transparent about its financials and accredited by charity evaluators.